A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations That Failed Standard Therapy
Latest Information Update: 19 Dec 2022
At a glance
- Drugs Pemigatinib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Dec 2022 New trial record